151 REDUCED DOSE AND DURATION OF SORAFENIB TREATMENT ARE ASSOCIATED TO TUMOR PROGRESSION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

Authors :: Valentina Cesario
M. Siciliano
Giuseppe Caracciolo
Michele A. Basso
Giovanni Gigante
F.R. Ponziani
G. Gasbarrini
G. Sarno
Alessandro Gasbarrini
M. Garcovich
B.E. Annichiarico
Mariachiara Campanale
Emanuele Rinninella
F. D'Aversa
Carlo Barone
Maria Assunta Zocco
T.A. Di Rienzo
Source :: Journal of Hepatology. 56:S65-S66
Publication Year :: 2012
Publisher :: Elsevier BV, 2012.

Subjects :: Oncology
medicine.medical_specialty
Hepatology
business.industry
Tumor progression
Internal medicine
Hepatocellular carcinoma
Sorafenib treatment
Medicine
In patient
business
medicine.disease
Reduced dose

Full Text Access

Tools